


# Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze

*Strados Labs' RESP™ Biosensor is currently being used in a clinical trial at Lurie Children's to determine if it can accurately detect wheezing in children.*



PHILADELPHIA, PA, UNITED STATES, September 26, 2023

[/EINPresswire.com/](https://EINPresswire.com/) -- [Strados Labs](#)<sup>1</sup> has partnered with [Ann & Robert H.](#)

[Lurie Children's Hospital of Chicago](#)<sup>2</sup> for a clinical trial to evaluate the

effectiveness of its RESP™ Biosensor in children presenting with wheeze. The RESP™ Biosensor – a novel wearable device used to remotely monitor lung sounds for asthma symptoms such as coughing and wheezing – will be evaluated against a 3M™ Littman digital stethoscope used for episodic auscultation.

Pediatric asthma affects more than 5 million children each year with 1 in 6 children visiting the emergency room annually due to complications, [according to the CDC](#)<sup>3</sup>. There is an urgent need for improved methods to detect and prevent exacerbations while patients are at home, particularly when asthma symptoms have become severe enough to warrant an ER visit or hospital admission. This study aims to leverage Strados Labs' RESP Biosensors, which has FDA clearance for use in adults, to potentially enhance the management of pediatric asthma and prevent hospitalizations.

Lurie Children's, the Midwest's largest freestanding children's hospital, and its research enterprise, Stanley Manne Children's Research Institute, are dedicated to reducing childhood morbidity associated with respiratory conditions, including asthma. Dr. Henry Schmidt and Lurie Children's have established an innovative collaborative partnership with Strados Labs to address a critical care gap in pediatric asthma management. Enrollment for the study began in August of 2023.

**Having a tool that allows clinicians to monitor asthma symptoms such as coughing and wheezing after discharge can enable earlier interventions and reduce hospitalizations.”**

— Nick Delmonico, CEO of Strados Labs

“We are thrilled to begin enrolling patients in this study in conjunction with Strados Labs,” said the study principal investigator Dr. Henry Schmidt. “This validation research represents an important steppingstone to further projects and ultimately clinical application of the RESP Biosensor. I feel that this technology represents an objective way to measure lung health in a safe, noninvasive format that is appealing to pediatric medicine. Utilizing this technology also has the potential to advance pulmonary diagnostics in a way that addresses healthcare disparities in our communities through improved access to care.”

The outcomes of this research will influence a follow-up study focusing on hospitalized children with asthma. This subsequent study will evaluate if the RESP Biosensor and the Strados™ Respiratory Care Platform can help determine readiness for reduction or escalation of therapy compared to current standard of care.

“From my experience as a former asthma patient, going home after an event can be scary and unsettling,” said Nick Delmonico, Co-founder & CEO at Strados Labs. “Having a tool that allows clinicians to objectively monitor symptoms such as coughing and wheezing against the care plan can offer patients and families a greater sense of security and reduce the risk of hospitalizations in the future.”

#####

## About Strados Labs

Strados Labs, Inc. is a medical technology company specializing in the enhancement of respiratory disease management. Utilizing advanced biosensors and machine learning algorithms, the company provides real-time monitoring of lung health. Strados Labs' FDA-cleared RESP Biosensor empowers clinicians to remotely detect changes in lung sound symptoms such as cough and wheeze that can indicate exacerbations, allowing for earlier interventions. In addition to its clinical applications, the RESP Biosensor and the Strados Respiratory Care Platform are employed in life sciences research to assess the effectiveness of treatments in clinical trials. Strados Labs is privately owned and based in Philadelphia, PA. For more information, visit [Stradoslabs.com](https://Stradoslabs.com) or follow us on LinkedIn and Twitter.

Research at Lurie Children's

Research at Ann & Robert H. Lurie Children's Hospital is conducted through Stanley Manne Children's Research Institute. Manne

Research Institute is focused on improving child health, transforming pediatric medicine, and ensuring healthier futures through the relentless pursuit of knowledge. Lurie Children's is a nonprofit organization committed to providing access to exceptional care for every child. It is ranked as one of the nation's top children's hospitals by U.S. News & World Report. Lurie Children's is the pediatric training ground for Northwestern University Feinberg School of Medicine.

Gabe Steerman  
Strados Labs  
gabe@stradoslabs.com  
Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

<sup>1</sup> <http://stradoslabs.com/>

<sup>2</sup> <https://www.luriechildrens.org/>

<sup>3</sup> <http://cdc.gov/asthma/vitalsigns.htm>

---

This press release can be viewed online at: <https://www.einpresswire.com/article/657710785/>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2023 Newsmatics Inc. All Right Reserved.